Key result
Genetic variants rs1879257 (ABCC5), rs13224758 (PRKAG2), rs10925391 (RYR2), and rs4149178 (SLC22A7) were associated with a 5- to 6-fold increased risk of cardiovascular toxicity in oncohematological patients receiving R-CHOP therapy.
Why the study?
To identify single nucleotide polymorphisms reliably associated with cardiovascular toxicity in oncohematological patients receiving antitumor immunochemotherapy.
Do specific genetic polymorphisms predict cardiovascular toxicity in oncohematological patients receiving R-CHOP therapy?
Cohort (n=34)
No
Do specific genetic polymorphisms predict cardiovascular toxicity in oncohematological patients receiving R-CHOP therapy?
Odds Ratio: 6.3 (95% CI 1.3–30.53)
p-value: p=0.02
Genetic screening for specific polymorphisms before R-CHOP therapy may help stratify the risk of cardiovascular toxicity in patients with non-Hodgkin's lymphoma.
Aim . To identify single nucleotide polymorphisms reliably associated with cardiovascular toxicity in oncohematological patients receiving antitumor immunochemotherapy. Material and methods . For the study, 34 patients with an established diagnosis of non-Hodgkin's B-cell follicular lymphoma were prospectively selected at the Clinic of the Samara State Medical University, who were indicated for antitumor immunochemotherapy according to the R-CHOP protocol. During the follow-up, the patients were divided into 2 following groups: the main group consisted of 12 patients with cardiovascular toxicity (mean age, 42,4 (2,8) years, including men — n=3 (25%)), the control group — 22 patients without cardiovascular toxicity (mean age, 39,8 (1,7), including men — n=8 (36%)). Cardiovascular toxicity was verified on the basis of a combination of specific cardiological complaints with a decrease in the left ventricular ejection fraction >10% from the baseline or in absolute terms less than 53% and/or a decrease in the left ventricular longitudinal systolic strain >12% from the baseline and/or an increase in NT-proBNP >125 pg/ml. Results . The study presents the identified genetic features in oncohematological patients in the context of cardiovascular toxicity. ABCC5 rs1879257, PRKAG2 rs13224758, RYR2 rs10925391 and SLC22A7 rs414917 variants had a significant association with an increased risk of cardiovascular toxicity in the target group of patients by 5-6 times. In addition, the ABCB1 rs2032582 variant showed the opposite effect and was associated with a reduced risk of cardiovascular complications, having a protective effect on the cardiovascular system. Conclusion . Although further studies are needed to confirm the diagnostic and prognostic significance of the detected genetic variants, the study results indicate the prospects of genetic screening before antitumor immunochemotherapy as a future tool for stratifying oncohematological patients and minimizing cardiovascular toxicity.
No takes yet. Share an insight, caveat, or question.
Gimatdinova et al. (2024) conducted a cohort in Non-Hodgkin's B-cell follicular lymphoma (n=34). Genetic polymorphisms (e.g., SLC22A7 rs4149178, ABCC5 rs1879257, PRKAG2 rs13224758, RYR2 rs10925391) vs. Absence of risk alleles was evaluated on Cardiovascular toxicity (decrease in LVEF >10% or <53%, decrease in LV GLS >12%, or increase in NT-proBNP >125 pg/ml) (OR 6.3, 95% CI 1.3-30.53, p=0.02). Genetic variants rs1879257 (ABCC5), rs13224758 (PRKAG2), rs10925391 (RYR2), and rs4149178 (SLC22A7) were associated with a 5- to 6-fold increased risk of cardiovascular toxicity in oncohematological patients receiving R-CHOP therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: